Open AccessMolecular Pharmacodynamics, Clinical Therapeutics, and Pharmacokinetics of Topiramate
Author(s) -
Shank Richard P.,
Maryanoff Bruce E.
Publication year - 2008
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/j.1527-3458.2008.00041.x
Subject(s) - pharmacodynamics , topiramate , pharmacology , pharmacokinetics , medicine , adverse effect , epilepsy , psychiatry
Topiramate (TPM; TOPAMAX ® ) is a broad‐spectrum antiepileptic drug (AED) that is approved in many world markets for preventing or reducing the frequency of epileptic seizures (as monotherapy or adjunctive therapy), and for the prophylaxis of migraine. TPM, a sulfamate derivative of the naturally occurring sugar D‐fructose, possesses several pharmacodynamic properties that may contribute to its clinically useful attributes, and to its observed adverse effects. The sulfamate moiety is essential, but not sufficient, for its pharmacodynamic properties. In this review, we discuss the known pharmacodynamic and pharmacokinetic properties of TPM, as well as its various clinically beneficial and adverse effects.